Status:
ACTIVE_NOT_RECRUITING
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
Lead Sponsor:
ReCode Therapeutics
Collaborating Sponsors:
Sano Genetics
Reverba
Conditions:
Primary Ciliary Dyskinesia
Eligibility:
All Genders
18+ years
Brief Summary
Primary purpose is to identify individuals who have PCD due to a genetic mutation within the DNAI1 and other genes of interest to help refer participants to future clinical studies for this rare disea...
Detailed Description
The aim of this study is to identify individuals with Primary ciliary dyskinesia (PCD) through a screening questionnaire that enriches for likely pathogenic gene mutations in DNAI1 and other genes of ...
Eligibility Criteria
Inclusion
- Participant must be at least 18 years old.
- Participant must have a prior diagnosis of PCD or be deemed eligible upon completion of the PCD-enrichment screening questionnaire.
- Participant must be under the care of an HCP for their PCD or symptoms potentially related to PCD.
- Participant must be able to read, write, and understand English, and reside in a country where the shipment of biological samples is allowed.
- Participant must be willing to be tested for genes involved in PCD.
- Participant must be willing to be notified of eligibility for clinical studies (if appropriate)
Exclusion
- In ability to meet any of the inclusion criteria
Key Trial Info
Start Date :
August 31 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT06172374
Start Date
August 31 2023
End Date
December 1 2025
Last Update
May 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
ReCode Therapeutics, Inc.
Menlo Park, California, United States, 94025